Form 4: P&G CFO Reports Future Stock Sale Under 10b5-1 Plan

Procter & Gamble's Chief Financial Officer, Andre Schulten, reported a future sale of 1.2969 shares of common stock on November 10, 2025, at a price of $146.3745 per share, executed under a Rule 10b5-1 plan.

Summary

• Andre Schulten, Chief Financial Officer of Procter & Gamble Co (PG), filed a Form 4 statement.
• The filing reports a transaction date of November 10, 2025.
• Schulten disposed of 1.2969 shares of Common Stock at a price of $146.3745 per share.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• Following the reported transaction, Schulten beneficially owns 6,869.3576 shares indirectly through a Retirement Plan Trustee and 53,992.0273 shares directly.

Sentiment

Score: 5

Explanation: The filing reports a routine, minor insider stock sale by the CFO, executed under a pre-arranged 10b5-1 plan. This is a standard disclosure and does not indicate significant positive or negative sentiment regarding the company's performance or outlook.

Positives

• The timely disclosure of insider trading activity, as required by SEC regulations, enhances transparency for investors.
• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-arranged and scheduled sale, which can mitigate concerns about opportunistic trading.

Negatives

• Andre Schulten, the Chief Financial Officer, sold a small number of common shares, which, while minor, represents a reduction in direct ownership.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The impact on shareholders is negligible due to the extremely small number of shares involved in the transaction.

Key Dates

Recommendation

The filing reports a routine, minor insider stock sale by the CFO, executed under a pre-arranged 10b5-1 plan. This transaction is too small to be considered material and does not provide new information significant enough to alter an investment thesis for Procter & Gamble. Therefore, a 'hold' recommendation remains appropriate based solely on this filing.

Keywords

Procter & Gamble, PG, insider trading, Form 4, stock sale, Andre Schulten, CFO, 10b5-1 plan